SEARCH:   Advanced

Blood, 15 June 2005, Vol. 105, No. 12, pp. 4845-4848. Prepublished online as a Blood First Edition Paper on March 1, 2005; DOI 10.1182/blood-2004-12-4700. This Article Full Text (PDF) All Versions of this Article: 2004-12-4700v1 105/12/4845    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Robillard, N. Articles by Bataille, R. Search for Related Content PubMed PubMed Citation Articles by Robillard, N. Articles by Bataille, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 9, 2004 Accepted February 10, 2005 Phenotypic characterization of the human myeloma cell growth fraction Nelly Robillard, Catherine Pellat-Deceunynck, and Regis Bataille* Departement de Recherche en Cancerologie, INSERM U601, Nantes, France; Central Laboratory of Hematology, University Hospital, Nantes, France Departement de Recherche en Cancerologie, INSERM U601, Nantes, France * Corresponding author; email: r-bataille{at}nantes.fnclcc.fr. In this study we quantified the proliferation rate of normal and malignant plasma cells (PC) by ex vivo incorporation of BrdU (labeling index, LI) using flow cytometry. We show that all bone marrow PC, either normal or malignant, include a subset of proliferating PC present within the CD45bright fraction. Indeed, medullary normal and malignant PC were always heterogeneous for CD45 expression, and proliferation was always restricted primarily to the CD45bright compartment. Moreover, an inverse correlation was found between LI or CD45 and Bcl-2 in both malignant and normal PC, the most proliferating CD45bright PC having the lowest Bcl-2 expression. We investigated expression of molecules of interest in multiple myeloma (MM) i.e., CD138, CD19, CD20, CD27, CD28, CD56 and CD11a, to further characterize the CD45bright fraction. Among all of these molecules, only CD11a was exclusively expressed by CD45bright proliferating myeloma cells. In conclusion, proliferating myeloma cells are characterized by the specific CD45bright CD11apos Bcl-2low phenotype. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Mateo, M. A. Montalban, M.-B. Vidriales, J. J. Lahuerta, M. V. Mateos, N. Gutierrez, L. Rosinol, L. Montejano, J. Blade, R. Martinez, et al. Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy J. Clin. Oncol., June 1, 2008; 26(16): 2737 - 2744. [Abstract] [Full Text] [PDF] A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, and C. Pellat-Deceunynck Osteoclasts support the survival of human plasma cells in vitro Int. Immunol., June 1, 2008; 20(6): 775 - 782. [Abstract] [Full Text] [PDF] A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica, March 1, 2008; 93(3): 431 - 438. [Abstract] [Full Text] [PDF] J. Moreaux, D. Hose, M. Jourdan, T. Reme, M. Hundemer, M. Moos, N. Robert, P. Moine, J. De Vos, H. Goldschmidt, et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines Haematologica, June 1, 2007; 92(6): 803 - 811. [Abstract] [Full Text] [PDF] K. L.M. Boylan, M. A. Gosse, S. E. Staggs, S. Janz, S. Grindle, G. S. Kansas, and B. G. Van Ness A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma Cancer Res., May 1, 2007; 67(9): 4069 - 4078. [Abstract] [Full Text] [PDF] G. Descamps, S. Wuilleme-Toumi, V. Trichet, C. Venot, L. Debussche, T. Hercend, M. Collette, N. Robillard, R. Bataille, and M. Amiot CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642 J. Immunol., September 15, 2006; 177(6): 4218 - 4223. [Abstract] [Full Text] [PDF] L. B. Baughn, M. Di Liberto, K. Wu, P. L. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. Cho, S. Ely, M. A.S. Moore, et al. A novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res., August 1, 2006; 66(15): 7661 - 7667. [Abstract] [Full Text] [PDF] K.-D. Wu, Y. S. Cho, J. Katz, V. Ponomarev, S. Chen-Kiang, S. J. Danishefsky, and M. A. S. Moore Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo PNAS, July 26, 2005; 102(30): 10640 - 10645. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020